Quince Therapeutics Secures $22 Million Private Placement, Raises Funds for A-T Trial and General Corporate Purposes.

Quince Therapeutics has priced a private placement of securities for up to $22 million, with $11.5 million in upfront proceeds and potential additional proceeds of $10.4 million if warrants are exercised in full. The financing is led by Nantahala Capital and will fund operations into the second quarter of 2026, or the second half of 2026 if warrants are exercised. Proceeds will be used for working capital, research and development, and general corporate purposes.